HDI Global US unveils new excess cover for life sciences

HDI Global Insurance Company, the US subsidiary of international commercial insurer, HDI Global, announced the launch of its excess Life Sciences Liability policy.

With up to $10M in available capacity, this enhanced solution provides customers with tailored cover for industry specific risks. Target classes include but are not limited to: biotechnology and specialty pharmaceutical manufacturers and distributors, – non-invasive, invasive and permanently implantable medical device manufacturers, – blood plasma manufacturers, and – contract manufacturing and contract development manufacturing organizations.

Brian Carlsen, who recently joined HDI as an Assistant Vice President will serve as its new US Life Science Lead. He will be responsible for building out the company’s book of business within the region. Brian brings 16 years of underwriting experience, with the last 10 being focused exclusively on Life Science placements. Prior to joining HDI, he was the Underwriting Manager and Referral Underwriter for the East region at a Fortune 500 carrier. Brian is a graduate of Fairfield University with a major in communications.

“HDI is committed to providing our insureds with bespoke solutions within the life sciences segment. The launch of our US Life Sciences division is another example of HDI’s continued focus on growth within the region and to act as a true Partner in Transformation for our clients in times of exceptional acceleration within the medical realm.” – Marco Hensel, Chief Underwriting Officer, HDI Global Insurance Company.

“HDI is excited to have Brian join our US casualty team. He brings extensive experience with small to large LS firms, underwriting accounts ranging from start-ups to large multinational corporations. His expertise will play a key role in HDI’s product line expansion within the US.” – Dani Maurer, Head of HDI’s Liability Global Risk Division.